Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast

被引:87
|
作者
Morales-Vasquez, Flavia
Gonzalez-Angulo, Ana Maria
Broglio, Kristine
Lopez-Basave, Horacio N.
Gallardo, Dolores
Hortobagyi, Gabriel N.
De La Garza, Jaime G.
机构
[1] Inst Nacl Cancerol, Dept Med Oncol, Mexico City, DF, Mexico
[2] Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA
[4] Inst Nacl Cancerol, Dept Surg, Mexico City, DF, Mexico
来源
BREAST JOURNAL | 2007年 / 13卷 / 06期
关键词
adjuvant chemotherapy; malignant phyllodes tumors of the breast; survival;
D O I
10.1111/j.1524-4741.2007.00510.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this study was to evaluate the role of adjuvant chemotherapy in malignant phyllodes tumors of the breast treated at the Instituto Nacional de Cancerologia a of Mexico. Twenty-eight patients with malignant phyllodes tumors of the breast enrolled in a observational study from January 1993 to December 2003 to receive four cycles of adjuvant chemotherapy with doxorubicin 65 mg/m(2) over 48 hours intravenous infusion and dacarbazine 960 mg/m(2) over 48 hours intravenous infusion (n = 17) versus observation (n = 11). All patients had surgical resection, and 38% had an axillary dissection. Seven patients (25%) received adjuvant radiotherapy. Log-rank test was used to test for differences in recurrence-free survival (RFS). The median patient age was 42 years (range, 2376 years). The median tumor size was 13 cm (range, 330 cm), and 46% of the tumors were in the left breast. At a median follow-up of 15 months (range, 281 months), there were seven recurrences and five deaths. The 5 year RFS rate was 58% (95% CI = 36% and 92%) for the patients who received adjuvant therapy and 86% (95% CI = 63% and 100%) for the patients who did not (p = 0.17). The median survival after recurrence was 6.5 months. Adjuvant chemotherapy with doxorubicin and dacarbazine did not affect patient survival. Future studies to identify relevant molecular targets should be implemented in order to define effective therapies for phyllodes tumors of the breast.
引用
收藏
页码:551 / 556
页数:6
相关论文
共 50 条
  • [41] Surgical Margins and Adjuvant Therapies in Malignant Phyllodes Tumors of the Breast: A Multicenter Retrospective Study
    Mathias Neron
    Christophe Sajous
    Simon Thezenas
    Sophie Piperno-Neumann
    Fabien Reyal
    Marick Laé
    Camille Chakiba
    Audrey Michot
    Nicolas Penel
    Charles Honoré
    Clémentine Owen
    François Bertucci
    Sébastien Salas
    Esma Saada-Bouzid
    Thibaud Valentin
    Emmanuelle Bompas
    Mehdi Brahmi
    Isabelle Ray-Coquard
    Jean-Yves Blay
    Nelly Firmin
    Annals of Surgical Oncology, 2020, 27 : 1818 - 1827
  • [42] Plasma carotenoids and recurrence-free survival in women with a history of breast cancer
    Rock, CL
    Flatt, SW
    Natarojan, L
    Thomson, CA
    Bardwell, WA
    Newman, VA
    Hollenbach, KA
    Jones, L
    Caan, BJ
    Pierce, JP
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) : 6631 - 6638
  • [43] Metaplastic Breast Cancer: Mastectomy Offers Greater Recurrence-Free Survival
    Rickles, Aaron S.
    Kostrzebski, Melissa
    Farkas, Rachel
    Choi, Daniel X.
    Wang, Xi
    Skinner, Kristin
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : 101 - 102
  • [44] The Impact of Adjuvant Chemotherapy on the Long-Term Prognosis of Breast Malignant Phyllodes Tumors: A Propensity Score-Matched Study
    Zhuang, Zilin
    Yilihamu, Ailifeire
    Li, Zhihua
    Lei, Rong
    Li, Xun
    Han, Mengjia
    Wei, Wei
    Li, Guangxin
    Ma, Zhen
    Zhang, Yulu
    Hu, Hui
    Xiao, Xiaoyun
    Nie, Yan
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22 (07):
  • [45] In-Breast Tumor Progression During Neoadjuvant Chemotherapy: Impact on and Factors Influencing Distant Recurrence-Free Survival
    Eckert, Kathryn M.
    Hoskin, Tanya L.
    Olson, Carrie A.
    Goetz, Matthew P.
    Boughey, Judy C.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (13) : 8856 - 8865
  • [46] SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment
    Huang, Yu-Hsiang
    Chu, Pei-Yi
    Chen, Ji-Lin
    Huang, Chun-Teng
    Lee, Chia-Han
    Lau, Ka-Yi
    Wang, Wan-Lun
    Wang, Yu-Ling
    Lien, Pei-Ju
    Tseng, Ling-Ming
    Liu, Chun-Yu
    JOURNAL OF CLINICAL MEDICINE, 2018, 7 (09)
  • [47] Effect of Chemotherapy on Overall and Recurrence-free Survival in Resectable Soft Tissue Sarcoma: A Meta-analysis
    Istl, A. C.
    Ruck, J. M.
    Morris, C. D.
    Levin, A. S.
    Meyer, C. F.
    Johnston, F. M.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : S180 - S180
  • [48] Identification of a novel locus associated with recurrence-free survival in Japanese breast cancer patients receiving adjuvant tamoxifen therapy
    Ishikawa, Toshihisa
    PHARMACOGENOMICS, 2012, 13 (09) : 994 - 995
  • [49] Impact of adjuvant chemotherapy on recurrence-free survival in patients with pT1a/b hormone-negative and HER2-positive breast cancer
    Migdady, Yazan
    Sikov, William M.
    Sakr, Bachir Joseph
    Olszewski, Adam J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Mammographic features at primary breast cancer diagnosis in relation to recurrence-free survival
    Lang, Kristina
    Sturesdotter, Li
    Bengtsson, Ylva
    Larsson, Anna-Maria
    Sartor, Hanna
    BREAST, 2024, 75